|
1
|
Sarkies P and Sale JE: Cellular epigenetic
stability and cancer. Trends Genet. 28:118–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Esteller M and Herman JG: Cancer as an
epigenetic disease: DNA methylation and chromatin alterations in
human tumours. J Pathol. 196:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang L and Pardee AB: Suberoylanilide
hydroxamic acid as a potential therapeutic agent for human breast
cancer treatment. Mol Med. 6:849–866. 2000.PubMed/NCBI
|
|
5
|
Kim MS, Kwon HJ, Lee YM, et al: Histone
deacetylases induce angiogenesis by negative regulation of tumor
suppressor genes. Nat Med. 7:437–443. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Butler LM, Agus DB, Scher HI, et al:
Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in
vitro and in vivo. Cancer Res. 60:5165–5170. 2000.PubMed/NCBI
|
|
7
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marks PA and Breslow R: Dimethyl sulfoxide
to vorinostat: Development of this histone deacetylase inhibitor as
an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duvic M and Vu J: Vorinostat: a new oral
histone deacetylase inhibitor approved for cutaneous T-cell
lymphoma. Expert Opin Investig Drugs. 16:1111–1120. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peart MJ, Tainton KM, Ruefli AA, et al:
Novel mechanisms of apoptosis induced by histone deacetylase
inhibitors. Cancer Res. 63:4460–4471. 2003.PubMed/NCBI
|
|
12
|
Shao Y, Gao Z, Marks PA and Jiang X:
Apoptotic and autophagic cell death induced by histone deacetylase
inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gui CY, Ngo L, Xu WS, Richon VM and Marks
PA: Histone deacetylase (HDAC) inhibitor activation of
p21WAF1 involves changes in promoter-associated
proteins, including HDAC1. Proc Natl Acad Sci USA. 101:1241–1246.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitsiades CS, Mitsiades NS, McMullan CJ,
et al: Transcriptional signature of histone deacetylase inhibition
in multiple myeloma: Biological and clinical implications. Proc
Natl Acad Sci USA. 101:540–545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan AN and Tomasi TB: Histone deacetylase
regulation of immune gene expression in tumor cells. Immunol Res.
40:164–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogbomo H, Michaelis M, Kreuter J, Doerr HW
and Cinatl J Jr: Histone deacetylase inhibitors suppress natural
killer cell cytolytic activity. FEBS Lett. 581:1317–1322. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deroanne CF, Bonjean K, Servotte S, et al:
Histone deacetylases inhibitors as anti-angiogenic agents altering
vascular endothelial growth factor signaling. Oncogene. 21:427–436.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alitalo K, Tammela T and Petrova TV:
Lymphangiogenesis in development and human disease. Nature.
438:946–953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mandriota SJ, Jussila L, Jeltsch M, et al:
Vascular endothelial growth factor-C- mediated lymphangiogenesis
promotes tumour metastasis. EMBO J. 20:672–682. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maula SM, Luukkaa M, Grenman R, Jackson D,
Jalkanen S and Ristamaki R: Intratumoral lymphatics are essential
for the metastatic spread and prognosis in squamous cell carcinomas
of the head and neck region. Cancer Res. 63:1920–1926. 2003.
|
|
21
|
Dadras SS, Paul T, Bertoncini J, et al:
Tumor lymphangiogenesis: a novel prognostic indaicator for
cutaneous melanoma metastasis and survival. Am J Pathol.
162:1951–1960. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valtola R, Salven P, Heikkila P, et al:
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in
breast cancer. Am J Pathol. 154:1381–1390. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang CA, Jedlicka P, Patrick AN, et al:
Six1 induces lymphangiogenesis and metastasis via upregulation of
VEGF-C in mouse models of breast cancer. J Clin Invest.
122:1895–1906. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Skobe M, Hawighorst T, Jackson DG, et al:
Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flaherty KT: Sorafenib in renal cell
carcinoma. Clin Cancer Res. 13:S747–S752. 2007. View Article : Google Scholar
|
|
26
|
Hanrahan EO and Heymach JV: Vascular
endothelial growth factor receptor tyrosine kinase inhibitors
Vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res.
13:S4617–S4622. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jimenez X, Lu D, Brennan L, et al: A
recombinant, fully human, bispecific antibody neutralizes the
biological activities mediated by both vascular endothelial growth
factor receptors 2 and 3. Mol Cancer Ther. 4:427–434. 2005.
|
|
28
|
Roberts N, Kloos B, Cassella M, et al:
Inhibition of VEGFR-3 activation with the antagonistic antibody
more potently suppresses lymph node and distant metastases than
inactivation of VEGFR-2. Cancer Res. 66:2650–2657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDonald DM: New antibody to stop tumor
angiogenesis and lymphatic spread by blocking receptor partnering.
Cancer Cell. 18:541–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rinderknecht M, Villa A, Ballmer-Hofer K,
Neri D and Detmar M: Phage-derived fully human monoclonal antibody
fragments to human vascular endothelial growth factor-C block its
interaction with VEGF receptor-2 and 3. PLoS One. 5:e119412010.
View Article : Google Scholar
|
|
31
|
Chilov D, Kukk E, Taira S, et al: Genomic
organization of human and mouse genes for vascular endothelial
growth factor C. J Biol Chem. 272:25176–25183. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Wei D, Huang S, et al:
Transcription factor Sp1 expression is a significant predictor of
survival in human gastric cancer. Clin Cancer Res. 9:6371–6380.
2003.PubMed/NCBI
|
|
34
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hung JJ, Wang YT and Chang WC: Sp1
deacetylation induced by phorbol ester recruits p300 to activate
12(S)-lipoxygenase gene transcription. Mol Cell Biol. 26:1770–1785.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang SA, Chuang JY, Yeh SH, et al: Heat
shock protein 90 is important for Sp1 stability during mitosis. J
Mol Biol. 387:1106–1119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li D, Marchenko ND and Moll UM: SAHA shows
preferential cytotoxicity in mutant p53 cancer cells by
destabilizing mutant p53 through inhibition of the HDAC6- Hsp90
chaperone axis. Cell Death Differ. 19:1268–1276. 2012.PubMed/NCBI
|
